Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

DNA Methylation Changes: An Early Biomarker for Methotrexate Response?

Key clinical point: Changes in DNA methylation at 4 weeks were associated with improvements in swollen joint count and CRP levels in RA patients at 6 months.

Major finding: Two differentially methylated positions that differed between good and poor methotrexate responders were identified in DNA samples taken after 4 weeks (P less than 1 × 10–6).

Study details: A multicenter, observational study of U.K. patients diagnosed with RA or inflammatory polyarthritis who began methotrexate for the first time.

Disclosures: The study was funded by the Medical Research Council and Versus Arthritis. The authors reported no conflicts of interest.

Citation:


Nair N et al. Rheumatology. 2019 Oct 10. doi: 10.1093/rheumatology/kez411.